Search This Blog

Monday, January 13, 2020

Guardant Health teams up with Amgen to develop CDx test

Guardant Health (GH -2.2%) will collaborate with Amgen (AMGN -1%) on developing a blood-based companion diagnostic (CDx) test for candidate AMG 510.
GH will pursue regulatory approvals in the U.S., Europe and Japan for its Guardant360 CDx for this use in metastatic non-small cell lung cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)